Prelude Capital Management’s PAVmed PAVM Stock Holding History

Prelude Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-56	Closed	-$54K	–	1747
2020 Q4	$54K	Buy	+56	New	+$47.9K	﹤0.01%	1200

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's PAVM Position: Q1 2021 in Review

Prelude Capital Management sold out of PAVmed (PAVM) in Q1 2021, closing a stake of 56 shares — an estimated $54K sold.

Prelude Capital Management first reported a position in PAVM in Q4 2020 and held it in 1 quarter. The position peaked at $54K in Q4 2020. 91 funds tracked by Wall St. Rank hold PAVM as of Q1 2021.

Prelude Capital Management reported no remaining PAVmed position as of Q1 2021 after selling out during the quarter.
Prelude Capital Management sold 56 PAVmed shares in Q1 2021, an estimated $54K.
Prelude Capital Management first reported a position in PAVmed in Q4 2020 and held it in 1 quarter.
Prelude Capital Management's PAVmed position peaked at $54K in Q4 2020.
91 funds tracked by Wall St. Rank held PAVmed as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.